SAN DIEGO, Feb. 21 /PRNewswire/ -- The benefits of plasma-depleted cord
blood stem cell products were the subjects of six abstracts presented this
week by StemCyte, Inc. and collaborators at the Bone Marrow Transplant
(BMT) Tandem Meetings in San Diego.
The abstracts reported data obtained in both pediatric and adult
patient populations that were treated with StemCyte's umbilical cord blood
(UCB) stem cell transplant products for multiple diseases, including
thalassemia, non-malignant diseases and blood cancers. StemCyte submitted
five of the abstracts, three of which were presented orally, with the sixth
submitted by researchers from the University of California, Los Angeles.
"The BMT Tandem Meetings were an excellent opportunity for StemCyte to
demonstrate the strength and breadth of applications of our UCB stem cell
products for treating patients with multiple diseases," said Kenneth J.
Giacin, chairman and chief executive officer of StemCyte. "We are pleased
that our research collaborators were able to present this important data."
Cord Blood Transplantation for Transfusion-Dependent Thalassemia
The first oral presentation, delivered by Dr. Tang-Her Jaing of Chang
Gung Children's Hospital, showed that UCB transplantation has resulted in
cures for patients with transfusion-dependent thalassemia in pediatric
patients. His results were drawn from the largest multi-institutional
series to evaluate umbilical cord blood transplantation as treatment for
thalassemia, which is a congenital disease that causes serious morbidity
and a significantly shortened life-span.
In the study, 58 thalassemics with a median age of 5 years were
analyzed in a comparison of the two leading strategies of reducing
umbilical cord blood volume, StemCyte's proprietary plasma depletion and
the standard red cell reduction method. Matched pair comparisons show that
patients treated with transplantation of plasma depleted cord blood
products had lower transplanted related mortality (p=0.001) and better
overall (p=0.001) and thalassemia-free survival (p=0.0001) compared to
those treated with standard red cell reduced cord blood. Dr. Jaing's data
showed that at experienced centers (greater than or equal to 10 cases)
using mostly unrelated donor HLA-mismatched plasma depleted cord blood,
there was a 96 plus or minus 4% cumulative incidence of neutrophil
engraftment, and 89 plus or minus 6% overall survival and thalassemia-free
Reduction of Incidences of Chronic Graft Versus Host Disease
Plasma-depleted cord blood can be effectively transplanted into
patients without first undergoing post-thaw washing, and was found to
reduce the incidence of extensive chronic Graft versus Host Disease
(cGvHD), according to research presented by Robert Chow, M.D., founder and
vice chairman of StemCyte.
In a study of 387 patients treated with plasma-depleted cord blood, 205
were provided with washed products, while 182 were treated with products
that had not been washed. Patients treated with the non-washed products had
a significantly lower rate of extensive cGvHD. Overall survival and
disease-free survival at one and three years were significantly higher for
participants in the non-wash group, while transplant-related mortality was
significantly lower in the non-wash group.
Treatment of Non-Malignant Disorders with Plasma-Depleted Cord Blood
In what was named one of the six Pediatric Best Abstracts, 120 children
received treatment for non-malignant disorders through a transplant of
plasma depleted cord blood products. The study, presented by Dr. Rosenthal,
M.D., Director of Pediatric Transplantation at the City of Hope National
Medical Center, reported that outstanding overall (88 plus or minus 4%) and
disease-free survival (84 plus or minus 5%) rates can be achieved if the
products were not washed prior to infusion.
In the study, cord blood products were used to treat 120 pediatric
patients with hemoglobinopathies, congenital immunodeficiency syndromes and
other non-malignant diseases. Two strategies pioneered by StemCyte were
used to increase the cell dose -- the use of plasma depleted cord blood
products and the avoidance of post-thaw wash.
Plasma-Depleted Cord Blood Effective in Treating Adult Malignancies
According to an abstract submitted by Auayporn Nademanee, M.D., of City
of Hope National Medical Center, single and double plasma-depleted cord
blood transplantations can be safely and effectively performed in adult
patients. In a study, 107 patients with a median age of 35 years were
treated for numerous forms of leukemia, including acute myelogenous
leukemia and acute lymphoblastic leukemia, and other malignant disorders.
The study also demonstrated that foregoing post-thaw wash decreased the
incidence of extensive cGvHD (p=0.05) without increasing the relapse rate.
Patients with double cord blood transplantation with plasma-depleted
products did not demonstrate higher rate of acute or chronic GvHD than
those who received single cord blood transplantation.
Matched Pair Comparison of StemCyte's Plasma Depleted versus Standard
Red Cell Reduced Cord Blood
An abstract presented by Michael Graham, M.D., of the University of
Arizona Medical Center demonstrates that StemCyte's proprietary
plasma-depleted cord blood may have potential advantages over the standard
cord blood products. In the study, 174 pediatric patients with hematologic
malignancies were treated with transplantation of plasma-depleted cord
blood in the study, while 100 patients received the standard red
cell-reduced cord blood.
To compare the benefits of plasma depletion and red cell reduction,
researchers matched patients from the two groups on the basis of disease
type, disease status, age, weight, and tissue type matching. With 92 pairs
of matched patients, Dr. Graham showed that patients transplanted with
plasma-depleted cord blood received higher cell dose, had lower
transplant-related mortality, superior engraftment and overall survival.
Stem Cell Transplantation for Treatment and Immune Reconstitution of
Tempe Chen, M.D. of UCLA Medical Center presented an abstract that
summarized collaborative work with StemCyte and City of Hope to evaluate
the capabilities of cord blood stem cells homozygous for the CCR5-delta 32
mutation to protect against HIV infection. With a StemCyte patent pending
on this technology, City of Hope researchers screened the StemCyte cord
blood inventory for the CCR5-delta 32 allele, and identified 30 homozygote
and 754 heterozygote cord blood products. Dr. Chen identified a number of
HIV patients that can be matched to the StemCyte homozygous CCR5-delta 32
inventory. StemCyte is working with City of Hope and UCLA to initiate a
clinical trial to test this technology.
StemCyte is a global leader in stem cell therapeutics with a marketed
umbilical cord blood stem cell transplantation product. Its proprietary
plasma depleted cord blood stem cell products have been used to cure
hundreds of patients with life-threatening diseases. With its partners,
StemCyte is actively involved in the development of new umbilical cord
blood based cell therapies and has the largest clinical study for using
unrelated cord blood transplantation for thalassemia, one of the most
common genetic diseases in the world. The company is one of two, and the
only commercial cord blood bank in the world dually accredited by AABB
(Formerly the American Association of Blood Banks) and Foundation for the
Accreditation of Cellular Therapy (FACT). StemCyte is also the only private
company contracted by the Federal Government to establish a National Cord
Blood Inventory. For more information, visit www.stemcyte.com.
StemCyte Media Contacts:
Russo Partners LLC
SOURCE StemCyte, Inc.